Cognition Therapeutics gets Nasdaq bid-price notice; Q3 net loss narrows to $4.1 million
Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, because its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027, to regain compliance, and the letter has no immediate effect on its listing. Third-quarter results showed a smaller net loss than a year earlier, but the company reported $31.5 million in cash as of September 30, 2026.
Key points
- Nasdaq letter dated November 3, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; compliance deadline is May 3, 2027
- Q3 2026 net loss was $4.1 million, or $(0.04) per share, versus $4.9 million, or $(0.06) per share, in Q3 2025
- Research and development expenses rose to $5.1 million from $3.8 million, while general and administrative expenses fell to $2.3 million from $2.6 million
- Cash and restricted cash equivalents were $31.5 million at September 30, 2026; the company estimates funding into the fourth quarter of 2027
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.